Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.

Chronic obstructive pulmonary disease (COPD) burden remains high in underdeveloped regions of China despite a decline in ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for COPD, ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD ... SoC AD treatment, Dupixent. Dupixent is ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler that’s prescribed for COPD. This article covers topics such as side effects, dosage ...

is showing significant potential in treating conditions such as asthma and COPD, with initial data expected to demonstrate enhanced dosing intervals compared to existing treatments like Dupixent.